+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


American Society of Clinical Oncology (ASCO) Annual Meeting, 2019 Assessment Report

  • ID: 4846142
  • Report
  • June 2019
  • Region: United States
  • 130 pages
  • Pharma Intelligence
The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications. Highlights included new data for Kisqali in HR+/HER2- breast cancer, Xtandi in prostate cancer, Lynparza in pancreatic cancer, and AMG510 in KRAS mutation-positive solid tumors. As with the past several years, PD-1/PD-L1 inhibitors were also featured prominently, with products like Keytruda, Opdivo, and Tecentriq each being included in multiple presentations. CAR-T therapies also remained in the spotlight, with this year’s conference showing their future potential in solid tumor indications.

This post-meeting report features commentary from our analysts on key presentations given at the conference as well as a compilation of all data events added to Biomedtracker in conjunction with the meeting.
Note: Product cover images may vary from those shown
Meeting Overview
  • Key Drug Analyses and Abstracts
  • Acute Lymphocytic Leukemia (ALL)
  • Yescarta (GILD, Phase II)
  • Acute Myelogenous Leukemia (AML)
  • CX-01 (Cantex Pharmaceuticals, Phase II)
  • Tibsovo (AGIO, Approved)
  • Bladder Cancer
  • Enfortumab Vedotin (Astellas, Phase III)
  • Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))
  • AG-881 (AGIO, Phase I) and Tibsovo (AGIO, Phase I)
  • DS-1001 (DSKYF, Phase I)
  • Breast Cancer
  • Capivasertib (AZN, Phase II)
  • H3B-6545 (EASLY, Phase II)
  • Kisqali (NVS, Approved)
  • Margetuximab (MDNX, Phase III)
  • Nerlynx (PBYI, Approved)
  • Perjeta (RHHBY, Approved)
  • Talzenna (PFE, Approved)
  • Cancer.33
  • ADU-S100 (ADRO, Phase I)
  • Cervical Cancer
  • LN-145 (IOVA, Phase II)
  • Venclexta (ABBV, Approved)
  • Diffuse Large B-Cell Lymphoma (DLBCL) – NHL
  • Mosunetuzumab (RHHBY, Phase II)
  • Gastric Cancer
  • Keytruda (MRK, Approved)
  • Cabometyx / Cometriq (EXEL, Investigator Initiated)
  • Head and Neck Cancer
  • ASP-1929 (Rakuten Medical, Phase III)
  • Keytruda (MRK, Approved)
  • SD-101 (DVAX, Suspended)
  • Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
  • Keytruda (MRK, Approved)
  • Melanoma
  • Contego (IOVA, Phase II)
  • PDR001 (NVS, Phase III)
  • Multiple Myeloma
  • AMG 420 (AMGN, Phase II)
  • Darzalex (JNJ, Approved)
  • Iberdomide (CELG, Phase II)
  • Isatuximab (SNY, Phase III)
  • Myelofibrosis (MF)
  • CPI-0610 (CNST, Phase II)
  • Fedratinib (CELG, NDA/BLA)
  • Non-Small Cell Lung Cancer (NSCLC)
  • BLU-667 (BPMC, Phase I)
  • CAN04 (CANTA:SS, Phase II)
  • Capmatinib (NVS, Phase II)
  • TAK-788 (TAK, Phase II)
  • Tepotinib (MKGAY, Phase II)
  • Ovarian Cancer
  • Lynparza (AZN, Approved)
  • Tivopath (Oncology) (AVEO, Phase II)
  • XMT-1536 (MRSN, Phase I)
  • Pancreatic Cancer
  • Abraxane (CELG, Approved)
  • Lynparza (AZN, Phase III)
  • Prostate Cancer
  • Darolutamide (BAYRY, NDA/BLA)
  • Erleada (JNJ, Approved)
  • Lynparza (AZN, Phase III)
  • Sagient Analysis American Society of Clinical Oncology (ASCO) 05/31/2019 (Abstract 5005)
  • Xtandi (Astellas 4503:JP, Approved)
  • Renal Cell Cancer (RCC)
  • Tivopath (Oncology) (AVEO, Phase III)
  • Sarcoma
  • Lartruvo (LLY, Approved)
  • NKTR-214 (NKTR, Investigator Initiated)
  • Tazemetostat (EPZM, NDA/BLA)
  • Small Cell Lung Cancer (SCLC)
  • Zepsyre (ZEL:SM, Phase III)
  • Solid Tumors
  • AMG 510 (AMGN, Phase I)
  • Cymraza (LLY Phase II)
  • Mesothelin-targeted CAR T Program (Atara) (ATRA, Phase I)
  • MORAb-202 (ESALY, Phase I)
  • mRNA-4157 (MRNA, Phase I)
  • NKTR-214 (NKTR, Phase II)
  • Repotrectinib (TPTX, Phase II)
  • List of Biomedtracker ASCO Events
Note: Product cover images may vary from those shown